Thus, the optimized NMDARs antagonist, UB-ALT-EV, offers a new opportunity for the treatment of AD, showing novel neuroprotective mechanisms including the reduction of proinflammatory microglial markers and the amelioration of astrocyte activation, additionally to calcium entry blockage (Fig. 5). The gene discussed is GPT; the disease is Alzheimer disease.